GAIL.NS GAIL (India) Limited
INR·Price 173.90·Mkt cap 1.14TComputed from the latest reported financials and the current market price.
Who's the real player?
A genuine play on this theme — most of its business sits right here.
Is the business healthy?
Shaky fundamentals — weak cash generation or a stretched balance sheet. Tread carefully.
- ⚠Weak FCF conversion (<50% of net income turns into free cash)
- Strong growth quality
- Healthy balance sheet
- Positive Piotroski score
Are the smart people buying?
No ownership-change data for this stock. Conviction is judged from capex and buyback signals alone.
- Strong promoter/insider stake
- Capex growth indicates belief in future
- Institutional holdings remain stable
What is management saying?
No earnings-call transcript or filings found for this stock.
Is the price right?
Intrinsic value 61.43 vs price 173.90 — screens expensive on a cash-flow DCF (-64.7% to intrinsic). The base DCF growth of 8% seems reasonable, but the reverse-DCF implied growth of 18.48% is extremely high and likely unrealistic for most companies.
| Intrinsic / share | 61.43 |
| Price | 173.90 |
| Upside to intrinsic | -64.7% |
| Reverse-DCF implied g | 18.5% |
Base FCF 34.44B · growth 8.0% · discount 12.0% · terminal 5.0%.
Sensitivity — intrinsic value / share
Each cell is the intrinsic value at that growth (across →) and discount rate (down ↓). Center ★ is the base case. Cells green = above price (cheap), red = below (expensive).
| Growth rate → | |||||
|---|---|---|---|---|---|
| Disc ↓ ╲ g | 4% | 6% | 8% | 10% | 12% |
| 10% | 65.45 | 82.61 | 102.67 | 126.07 | 153.33 |
| 11% | 48.73 | 62.52 | 78.58 | 97.28 | 119.01 |
| 12% | 36.78 | 48.18 | ★ 61.43 | 76.81 | 94.64 |
| 13% | 27.81 | 37.44 | 48.6 | 61.53 | 76.49 |
| 14% | 20.82 | 29.09 | 38.66 | 49.71 | 62.47 |
Through the masters' eyes
Each investor's numeric rules, checked against this stock's metrics: exact math, no guesswork. Tap one to see which rules pass, fail, and what to judge yourself.
Financial statements (INR)
↗ sourceCash-flow lines highlighted — we trust cash over reported profit.
| Line | 2026 | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | 1.42T | 1.42T | 1.33T | 1.45T | — |
| Operating income | 76.75B | 116.23B | 110.78B | 49.79B | — |
| EBITDA | 145.24B | 206.35B | 170.33B | 104.23B | — |
| Net income | 75.82B | 124.50B | 98.99B | 56.16B | — |
| Operating cash flow | 112.49B | 157.27B | 125.86B | 32.05B | — |
| Capex | -88.06B | -79.22B | -125.01B | -88.31B | — |
| Free cash flow | 24.42B | 78.05B | 845.50M | -56.26B | — |
| Total assets | 1.41T | 1.33T | 1.25T | 1.08T | — |
| Total equity | 890.50B | 849.98B | 769.97B | 649.27B | — |
| Total debt | 248.31B | 215.95B | 217.94B | 178.16B | — |
| Cash & equivalents | 9.59B | 13.17B | 11.46B | 2.44B | — |